The European Patent Office (EPO) has published patent application EP4630033A1, titled "Novel Human Antiviral Genes Related to the Eleos and Lamassu Prokaryotic Systems." This publication, dated March 18, 2026, concerns genetic material and its potential application in antiviral therapies. The applicants are Institut National de la Santé et de la Recherche Médicale, Université Paris Cité, and Institut Curie.

This is a patent publication, not a regulatory rule or enforcement action. It does not impose new compliance obligations or deadlines on regulated entities. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in antiviral research and development, may wish to review this patent application for potential intellectual property insights or competitive intelligence. The application covers designated states within the European Union.